▎WuXiEdited by Kant Content Team

Recently, the positive results of the Phase 3 clinical trial named WAYPOINT for Tezspire (tezepelumab), a "first-in-class" monoclonal antibody jointly developed by AstraZeneca and Amgen for patients with chronic rhinosinusitis with nasal polyps (CRSwNP), were announced.Analysis shows that Tezspire significantly reduced the size of patients' nasal polyps and alleviated nasal congestion symptoms compared to placebo.Detailed data will be presented at an upcoming medical conference and shared with regulatory authorities.

CRSwNP is a complex inflammatory disease characterized by persistent inflammation of the nasal mucosa, accompanied by benign nasal polyp growth.Nasal polyps can block the nasal cavity, leading to breathing difficulties, olfactory disorders, runny nose, facial pain, sleep disorders, and other adverse effects on quality of life.Epithelial dysfunction and inflammation are key features of chronic rhinosinusitis, impairing the epithelium's ability to act as a physical and immune barrier against the external environment.

WAYPOINT is a randomized, double-blind trial designed to evaluateSkinPlace a betInjectionEfficacy and Safety of Tezspire vs Placebo in Adults with Severe CRSwNP. Trial participants remained symptomatic despite standard of care intranasal corticosteroids (INCS). Analysis shows,Tezspire demonstrated statistically significant and clinically meaningful improvements in nasal polyp size and nasal congestion severity compared to placebo.The safety and tolerability of Tezspire in this trial were consistent with the known characteristics of the drug.

Tezspire is a "first-in-class" human monoclonal antibody that targets and inhibits thymic stromal lymphopoietin (TSLP).TSLP is a key epithelial cytokine, positioned at the apex of multiple inflammatory cascades, and is crucial in the initiation and persistence of allergic, eosinophilic, and other types of endothelial inflammation associated with severe asthma and other inflammatory diseases. Tezspire has been approved in the United States, the European Union, and nearly 60 countries/regions for add-on maintenance treatment in adults and children aged 12 years and older with severe asthma. In addition to CRSwNP, Tezspire is also being developed for other potential indications, includingChronic Obstructive Pulmonary Disease(COPD) and Eosinophilic Esophagitis (EoE).

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.

[1] Tezspire met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps. Retrieved November 9, 2024 from https://www.astrazeneca.com/media-centre/press-releases/2024/tezspire-nasal-polyps-trial-met-primary-endpoints.html

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media platforms, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the "WuXi AppTec" WeChat Official Account to obtain the reprint guidelines.